Bio
Mads Melbye, MD, DMSc, is visiting Professor in the Department of Pediatrics at Stanford University School of Medicine. He is also Director of the Danish Cancer Institute (DCI), Research Director at the Danish Cancer Society in Denmark, and Professor in Medical Epidemiology at Copenhagen University in Denmark. From 2016-2020 he was President and CEO at Statens Serum Institut, Copenhagen, Denmark. Previous positions at e.g. the National Cancer Institute, NIH, USA, before he became State Epidemiologist in Denmark, and later Head of Department of Epidemiology Research, and Division Director of Epidemiology and Disease Surveillance, Statens Serum Institut. Previous academic positions as Danish Research Council Professor, NORFA professor, and Foreign Adjunct Professor at Karolinska Institute in Sweden. He has written more than 700 publications (H-index: 108/132 (Web of Science/Google scholar) and is the Dane with most papers in high impact journals in general medicine (NEJM, Lancet, JAMA). He is among the worlds top 2% of scientists as listed in the AD Scientific Index 2023. He is knighted by Her Majesty Queen Margrethe II of Denmark, and has recieved e.g. the Novo Nordisk Prize, the large Erhoff Prize, and the Anders Jahre Prize (young researchers), Oslos, Norway. He is e.g. chairman of the scientific committee at the Danish Health Insurance Fund, member of the scientific advisory board for Oslo University Hospital, member of the A.P. Møller and Chastine Mc-Kinney Møller Foundation (medicine), and board member of the Norwegian Cancer Registry. Has previously served as e.g. chairman of the Governing Council, WHO's International Agency for Research on Cancer in Lyon, France, chairman of the Nordic Medical Research Council’s coordinating body (NOS-M), vice-chairman of the Danish Medical Research Council, chairman of the Ministry of Science, Technology and Innovation's committee on Registry Research (KOR), chairman of the Scientific Council, IARC, Lyon, France, and member of the Novo Nordisk Prize Committee. Together with Professor Stephen Quake he founded Mirvie Inc. in 2018, a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health.
